替罗非班对急性心梗冠脉介入术后C反应蛋白的影响研究.docVIP

精品论文 参考文献 替罗非班对急性心梗冠脉介入术后C反应蛋白的影响研究 谷永江 北京市昌平区中医医院100020 摘要：目的：探讨替罗非班对急性心肌梗死行冠脉介入术（PCI）后C 反应蛋白的影响。方法：将我院2010年3 月-2012年3 月收治的114 例急性心肌梗死 行PCI 介入术患者随机分为两组，对照组采取常规治疗，观察组在此基础上加用替罗非班，检测并比较两组患者治疗前后血清CRP 水平。结果：两组患者治疗后血清CRP 水平较治疗前明显降低（Plt;0.05）；观察组治疗后血清CRP 水平为（3.22plusmn;0.62）mg/L，明显低于对照组的6.44plusmn;1.32（Plt;0.05）。结论：替罗非班用于急性心肌梗死冠脉介入术可明显降低患者血清炎症因子水平，减少心肌损伤，具有较好的临床应用价值。 关键词：替罗非班；急性心肌梗死；冠脉介入术；C 反应蛋白 The impact of tirofiban for C-reactive protein after percutaneous transluminal coronary intervention (PCI) of acute myocardial infarction (AMI) [Abstract] Objective: To investigate the impact of tirofiban for C-reactive protein in acute myocardial infarction (AMI) patients undergoing percutaneous transluminal coronary intervention (PCI). Methods: 114 patients with AMI undergoing PCI were randomly divided into two groups in our hospital from March 2010 to March 2012, the control group was given conventional treatment while the observation group was given tirofiban on the basis of the control group, and the serum CRP levels before and after treatment were measured and compared. Results: After treatment, serum CRP levels significantly lower than before (Plt;0.05); after treatment, the serum CRP levels of the observation group were (3.22plusmn;0.62) mg/L significantly lower than the control group (Plt;0.05). Conclusion: Tirofiban for AMI of PCI can significantly reduce serum levels of inflammatory factors, reduce myocardial injury, and it has better clinical value. [Key words] tirofiban; acute myocardial infarction (AMI); percutaneous transluminal coronary intervention (PCI); C-reactive protein 急性心肌梗死（AMI）是临床上较为常见的心脑血管疾病之一， 具有较高的发病率，且随近年来人们生活水平的不断提高其发病率呈 逐年上升的趋势，患者多预后较差[1]。经皮冠状动脉介入术（PCI） 作为目前临床治疗急性心肌梗死的有效手段之一，可快速、及时的开 通梗死血管，恢复前向血流，改善心肌缺血以减少致残率和死亡率， 也是心肌梗死患者血管重建的最有效措施，但对术后炎症反应的抑制 是临床关注的重点，影响患者预后[2-3]。本研究对我院2010 年3 月 -2012年3月收治的急性心肌梗死行PCI手术患者给予替罗非班治疗 取得了满意效果，现将研究结果报道如下。 1 资料与方法